Irving Institute Announces 2017-2018 Translational Therapeutics Accelerator Pilot Awardees

August 1, 2018

The Irving Institute for Clinical and Translational Research, home to Columbia University’s Clinical and Translational Science Award (CTSA) Program hub, announces the winners of the 2017-2018 Translational Therapeutics Accelerator pilot awards.

The Translational Therapeutics Accelerator (TRx) Pilot Award provides investigators with the resources to position their therapeutic discoveries for future commercial value. Awardees are expected to develop a commercially relevant product profile. The pilot awardees are:

Engineered Deubiquitinases: A Novel Therapeutic Platform

  • Henry M. Colecraft, PhD, Associate Professor of Physiology & Cellular Biophysics
  • Alice Prince, MD, Professor of Pediatrics in Pharmacology 

Theridase: Therapy for Cerebral Edema and Increased Intracranial Pressure

  • Steve Kernie, MD, Professor of Pediatrics in Neurology
  • Barclay Morrison, PhD, Professor of Biomedical Engineering 

MAP4K2 as a Therapeutic Target of Multiple Myeloma and Development of Novel Targeting Drugs

  • Suzanne Lentzsch, MD, PhD, Associate Professor of Clinical Medicine
  • Don Landry, MD, PhD, Samuel Bard Professor of Medicine

CalCardia: Fixing Abnormal Calcium Handling in Sick Hearts

  • Steven Marx, MD, Professor of Medicine in Pharmacology
  • Alexander Kushnir, MD, PhD, Cardiac Electrophysiology Fellow

Optimization of the Isopomiferin Scaffold as an HDAC-based Precision Medicine for MycNAMP Nueroblastoma 

  • Brent Stockwell, PhD, Professor of Biological Sciences and Chemistry
  • Darrell Yamashiro, MD, PhD, Associate Professor of Pathology & Cell Biology and Pediatrics

Injectable Cell-based Therapy of Micro-Tissues for Extremely Rapid Recovery of Ischemic Conditions

  • Samuel Sia, PhD, Professor of Biomedical Engineering
  • Danielle Bajakian, MD, Assistant Professor of Surgery 

Tags

Campus News, Research, NIH/NCATS, Funding, Pilot Awards, Translational Therapeutics